C-Path and CDISC launch CFAST

Friday, September 14, 2012 12:35 PM

The Clinical Data Interchange Standards Consortium (CDISC), a global non-profit charitable organization, and Critical Path Institute (C-Path), a Tucson, Ariz.-based non-profit organization committed to improving human health and well-being, have launched their joint Coalition For Accelerating Standards and Therapies (CFAST), a follow-up to the partnership agreement signed earlier this year.

CFAST is an initiative to accelerate clinical research and medical product development by facilitating the creation and maintenance of data standards, tools and methods for conducting research in therapeutic areas important to public health. To date, CDISC has either released draft or provisional standards packages covering five different disease areas: Parkinson’s, Alzheimer’s, tuberculosis, virology and pain. Upcoming releases will include therapeutic area standards packages for polycystic kidney disease, cardiovascular disease and schizophrenia.

“CFAST will serve as a strong partner assisting the FDA in meeting their PDUFA V performance goals of ‘improving efficiency of human drug review through required data submissions standardization.’ We are optimistic that this partnership will truly make a difference in the review process,” said Dr. Carolyn Compton, president and CEO of C-Path.

Interchange attendees can participate in discussions with a number of people who are actively working to improve public health. Keynote speakers include Dr. Janet Woodcock of the FDA and Ann Martin of Europe’s Innovative Medicines Initiative (IMI). Patient advocacy groups with participating representation include One Mind for Research, DataSphere (a biopharma data sharing initiative), the Vradenburg Foundation and the Michael J. Fox Foundation. Other participating organizations are the Japan Translational Research Informatics Institute, the U.S. National Cancer Institute, the Texas eHealth Alliance, Duke University and the University of Rochester.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 2

Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity

FDA action plan seeks to close gap in women and minority patient representation in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs